Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Disclaimer: The information provided on Peptide Mind is for educational purposes only and is not a substitute for professional medical advice
If someone cannot clearly see the area or maintain control, it is not the best choice for self-administration
Clinic Consultation charges
A small phase II trial reported limited efficacy of T-DM1 monotherapy in 15 relapsed HER2 -altered NSCLC patients with an objective response rate (ORR) of 6.7% and median progression-free survival (PFS) and overall survival (OS) of 2 (95% confidence interval [CI], 1.4 to 4) and 10.9 months (95% CI, 4.4 to 12), respectively
US$ 20.40
US$ 20.21
US$ 21.56
US$ 29.15
US$ 27.80
US$ 28.82
US$ 23.74
US$ 20.23
US$ 28.95
